Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users

Author(s):Show less -

de Souza, Francis Ribeiro ^[1] ; Dos Santos, Marcelo Rodrigues ^[1] ; Porello, Rafael Armani ^[1] ; Peixoto da Fonseca, Guilherme Wesley ^[1] ; Carrari Sayegh, Ana Luiza ^[1] ; Lima, Thais Pinheiro ^[1] ; Ferreira, Fabiana Dias ^[2] ; de Oliveira, Tiago Franco ^[3] ; Yonamine, Mauricio ^[4] ; Takayama, Liliam ^[5] ; Rodrigues Pereira, Rosa Maria ^[5] ; Negrao, Carlos Eduardo ^[1] ; Passarelli, Marisa ^{[2, 6]} ; Rochitte, Carlos Eduardo ^[1] ; de Nazare Nunes Alves, Maria Janieire ^[1]

Affiliation

^[1] Univ Sao Paulo, Inst Coracao InCor, Hosp Clin, Fac Med, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Hosp Clin, Lab Lipides LIM 10, Fac Med, Sao Paulo - Brazil

^[3] Univ Fed Ciencias Saude Porto Alegre, Dept Farmacociencias, Porto Alegre, RS - Brazil

^[4] Univ Sao Paulo, Dept Anal Clin & Toxicol, Fac Ciencias Farmaceut, Sao Paulo, SP - Brazil

^[5] Univ Sao Paulo, Hosp Clin, Lab Metab Osseo, Fac Med, Sao Paulo - Brazil

^[6] Univ Nove Julho, Programa Posgrad Med, Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: ATHEROSCLEROSIS; v. 283, p. 100-105, APR 2019.
• Web of Science Citations: 1

Abstract

Background and aims: Anabolic androgenic steroids (AAS) have been associated with coronary artery disease (CAD). AAS abuse leads to a remarkable decrease in high-density lipoprotein (HDL) plasma concentration, which could be a key factor in the atherosclerotic process. Moreover, not only the concentration of HDL, but also its functionality, plays a pivotal role in CAD. We tested the functionality of HDL by cholesterol efflux and antioxidant capacity. We also evaluated the prevalence of CAD in AAS users. Methods: Twenty strength-trained AAS users (AASU) age 29 +/- 5 yr, 20 age-matched strength-trained AAS nonusers (AASNU), and 10 sedentary controls (SC) were enrolled in this cross-sectional study. Functionality of HDL was evaluated by C-14-cholesterol efflux and the ability of HDL in inhibiting LDL oxidation. Coronary artery was evaluated with coronary computed tomography angiography. Results: Cholesterol efflux was lower in AASU compared with AASNU and SC (20 vs. 23 vs. 24%, respectively, p < 0.001). However, the lag time for LDL oxidation was higher in AASU compared with AASNU and SC (41 vs 13 vs 11 min, respectively, p < 0.001). We found at least 2 coronary arteries with plaques in 25% of AASU. None of the AASNU and SC had plaques. The time of AAS use was negatively associated with cholesterol efflux. Conclusions: This study indicates that AAS abuse impairs the cholesterol efflux mediated by HDL. Long-term AAS use seems to be correlated with lower cholesterol efflux and early subclinical CAD in this population. (AU)

• FAPESP's process: 12/10527-3 - Impact of self-administrating anabolic androgenic on cardiovascular system
• Grantee: Maria Janieire de Nazaré Nunes Alves
• Support Opportunities: Regular Research Grants
• FAPESP's process: 16/24306-0 - The effect of NEPRIlysin (LCZ696) on EXercise TOLerance, muscle vasodilatation, muscle strength and body composition in patients with Heart Failure - NEPRIExTol-HF Trial
• Grantee: Marcelo Rodrigues dos Santos
• Support Opportunities: Scholarships in Brazil - Post-Doctoral